Publications by authors named "Daniel Cimbora"

Claim this Profile
I
Inebilizumab for Treatment of IgG4-Related Disease.
John H Stone, Arezou Khosroshahi, Wen Zhang, Emanuel Della Torre, Kazuichi Okazaki, Daniel Cimbora

N Engl J Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.
Jeffrey L Bennett, Sean J Pittock, Friedemann Paul, Ho Jin Kim, Sarosh R Irani, Daniel Cimbora

Ann Clin Transl Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Bruce A C Cree, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Daniel Cimbora

Lancet Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
Cory Perugino, Emma L Culver, Arezou Khosroshahi, Wen Zhang, Emanuel Della-Torre, Daniel Cimbora

Rheumatol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Ho Jin Kim, Orhan Aktas, Kristina R Patterson, Schaun Korff, Amy Kunchok, Daniel Cimbora

Ann Clin Transl Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Orhan Aktas, Hans-Peter Hartung, Michael A Smith, William A Rees, Kazuo Fujihara, Daniel Cimbora

J Neurol Neurosurg Psychiatry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Brian G Weinshenker, Dean M Wingerchuk, Ari J Green, Jeffrey L Bennett, Ho Jin Kim, Daniel Cimbora

Mult Scler· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Jeffrey L Bennett, Orhan Aktas, William A Rees, Michael A Smith, Michele Gunsior, Daniel Cimbora

EBioMedicine· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
Li Yan, Bing Wang, Dewei She, Ben Mitchell, Ryan Criste, Daniel Cimbora

Br J Clin Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Mary Rensel, Aram Zabeti, Maureen A Mealy, Daniel Cimbora, Dewei She

Mult Scler· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis.
Li Yan, Holly Kimko, Bing Wang, Daniel Cimbora, Eliezer Katz

Clin Pharmacokinet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Eoin P Flanagan, Michael Levy, Eliezer Katz, Daniel Cimbora, Jorn Drappa

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Romain Marignier, Sean J Pittock, Friedemann Paul, Ho Jin Kim, Jeffrey L Bennett, Daniel Cimbora

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Bruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Daniel Cimbora

Mult Scler· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Daniel Cimbora

Neurol Neuroimmunol Neuroinflamm· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Bruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Daniel Cimbora

Lancet· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.
Thomas G Forsthuber, Daniel M Cimbora, John Nolan Ratchford, Eliezer Katz, Olaf Stüve

Ther Adv Neurol Disord· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Elena Schiopu, Soumya Chatterjee, Vivien Hsu, Armando Flor, Daniel Cimbora

Arthritis Res Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
Matthew G Bursavich, David Dastrup, Mark Shenderovich, Kraig M Yager, Daniel M Cimbora

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor.
Se-Ho Kim, Ashok Bajji, Rajendra Tangallapally, Benjamin Markovitz, Richard Trovato, Daniel Cimbora

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors.
D Vijay Kumar, Christophe Hoarau, Matthew Bursavich, Paul Slattum, David Gerrish, Daniel M Cimbora

Bioorg Med Chem Lett· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.
Keith D Tardif, Aaron Rogers, Jared Cassiano, Bruce L Roth, Daniel M Cimbora

Mol Cancer Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxindole derivatives as inhibitors of TAK1 kinase.
Jeffrey W Lockman, Matthew D Reeder, Rosann Robinson, Patricia A Ormonde, Daniel M Cimbora

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97).
Matthew G Bursavich, Daniel P Parker, J Adam Willardsen, Zhong-Hua Gao, Thaylon Davis, Daniel M Cimbora

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marine natural product libraries for high-throughput screening and rapid drug discovery.
Tim S Bugni, Burt Richards, Leen Bhoite, Daniel Cimbora, Mary Kay Harper

J Nat Prod· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis